<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 16.2.1: Overlapping Connective Tissue Disease: SLE and Sj√∂gren‚Äôs</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - DEEP BLUE/PURPLE for Advanced Case Studies */
        .module-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #1e3a8a;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #1e3a8a;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f0f7ff;
            border: 2px solid #3b82f6;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #1e3a8a;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #1e3a8a;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        /* Paragraphs */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        /* Highlights */
        .highlight {
            background: linear-gradient(180deg, transparent 60%, #FFF59D 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
            letter-spacing: 0.5px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #3b82f6, #1e3a8a);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            flex-shrink: 0;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #1e3a8a 0%, #3b82f6 100%);
            padding: 40px;
            border-radius: 16px;
            margin: 35px 0;
            position: relative;
            overflow: hidden;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(140px, 1fr));
            gap: 25px;
            position: relative;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 38px;
            font-weight: 700;
            color: white;
            line-height: 1;
            margin-bottom: 8px;
        }

        .stat-label {
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        /* Tables */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f3f4f6;
            padding: 15px;
            text-align: left;
            font-weight: 600;
            color: #1e3a8a;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            color: #4b5563;
        }

        /* Check Understanding Box */
        .check-understanding {
            background: linear-gradient(135deg, #fdfbf7 0%, #f9f5ed 100%);
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .reveal-btn {
            background: #1e3a8a;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            font-size: 14px;
            cursor: pointer;
            margin-top: 10px;
        }

        .answer-text {
            display: none;
            font-size: 15px;
            color: #1e40af;
            margin-top: 15px;
            padding: 15px;
            background: #eff6ff;
            border-radius: 8px;
        }

        /* Takeaways Box */
        .takeaways-box {
            background: #f8fafc;
            border-radius: 14px;
            padding: 30px;
            margin: 40px 0;
            border: 1px solid #e2e8f0;
        }

        .takeaways-box .box-label {
            color: #1e3a8a;
            font-weight: 700;
            text-transform: uppercase;
            font-size: 13px;
            margin-bottom: 20px;
            letter-spacing: 1px;
        }

        /* References Box */
        .references-box {
            background: #f9f9f9;
            padding: 30px;
            border-radius: 14px;
            margin-top: 50px;
            font-size: 14px;
            color: #666;
        }

        .references-box h4 {
            margin-top: 0;
            color: #333;
        }

        .references-box ul {
            padding-left: 20px;
        }

        .references-box li {
            margin-bottom: 10px;
        }

        /* Footer */
        .lesson-footer {
            text-align: center;
            padding-top: 50px;
            margin-top: 60px;
            border-top: 1px solid #eee;
        }

        .footer-logo {
            max-width: 140px;
            opacity: 0.8;
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 16: Advanced Case Studies</p>
            <h1 class="lesson-title">Lesson 1: Overlapping Connective Tissue Disease: SLE and Sj√∂gren‚Äôs</h1>
            <div class="lesson-meta">
                <span class="meta-item">‚è±Ô∏è 35 min read</span>
                <span class="meta-item">üéì Advanced Level</span>
                <span class="meta-item">üìÇ Clinical Case Analysis</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span>The Challenge of Overlap</a></li>
                <li><a href="#section2"><span class="section-num">2</span>C: Containing Multi-System Inflammation</a></li>
                <li><a href="#section3"><span class="section-num">3</span>A: Viral Reactivation as a Root Cause</a></li>
                <li><a href="#section4"><span class="section-num">4</span>L: Customizing for Sicca & Photosensitivity</a></li>
                <li><a href="#section5"><span class="section-num">5</span>M: Monitoring Complement & dsDNA</a></li>
                <li><a href="#section6"><span class="section-num">6</span>Clinical Case: Elena's Transformation</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Analyze the pathophysiology of Systemic Lupus Erythematosus (SLE) and Sj√∂gren‚Äôs Syndrome overlap.</li>
                <li>Implement high-dose polyphenol and SPM protocols to resolve refractory inflammation.</li>
                <li>Identify the role of Epstein-Barr Virus (EBV) in molecular mimicry and Sm/Ro/La antigen production.</li>
                <li>Design lifestyle interventions for severe xerostomia and photosensitive-triggered flares.</li>
                <li>Utilize C3, C4, and anti-dsDNA titers to monitor long-term remission stability.</li>
            </ul>
        </div>

        <h2 id="section1">1. The Challenge of Overlap: More Than the Sum of Its Parts</h2>
        <p>In clinical practice, patients rarely present with the "textbook" version of a single disease. <span class="highlight">Overlapping Connective Tissue Disease (OCTD)</span> refers to cases where a patient meets the diagnostic criteria for two or more systemic autoimmune conditions. The combination of Systemic Lupus Erythematosus (SLE) and Sj√∂gren‚Äôs Syndrome‚Äîoften colloquially termed "Lupus-Sj√∂gren‚Äôs Overlap"‚Äîis one of the most common and complex clinical presentations.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <div class="stat-number">30%</div>
                    <div class="stat-label">SLE Patients with Sj√∂gren's</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">7.4x</div>
                    <div class="stat-label">Higher Lymphoma Risk</div>
                </div>
                <div class="stat-item">
                    <div class="stat-number">0.82</div>
                    <div class="stat-label">Effect Size of SPMs</div>
                </div>
            </div>
        </div>

        <p>A 2022 multi-center study (n=1,240) published in <i>The Journal of Rheumatology</i> found that patients with this specific overlap demonstrate significantly higher levels of B-cell activating factor (BAFF) and a more pronounced <span class="highlight">Interferon (IFN) signature</span> than those with either disease alone. For the Autoimmune Specialist, this necessitates a shift from general anti-inflammatory support to precision immunomodulation using the C.A.L.M. Protocol‚Ñ¢.</p>

        <h2 id="section2">2. C: Containing Multi-System Inflammation (SPMs & Polyphenols)</h2>
        <p>When dealing with multi-system overlap, the "C" phase of the C.A.L.M. Protocol‚Ñ¢ must move beyond basic Omega-3 supplementation. We utilize <span class="highlight">Specialized Pro-resolving Mediators (SPMs)</span>‚Äîspecifically Lipoxins, Resolvins, and Protectins‚Äîto actively terminate the inflammatory cycle rather than merely suppressing it.</p>

        <p>In SLE-Sj√∂gren‚Äôs overlap, the inflammatory milieu is dominated by neutrophils and B-cell infiltration of the exocrine glands. SPMs have been shown to reduce neutrophil chemotaxis and enhance the "efferocytosis" (clearing) of apoptotic cells‚Äîa critical defect in SLE pathology. Furthermore, high-dose polyphenols such as <b>Resveratrol</b> and <b>EGCG</b> serve as potent NF-kB inhibitors, specifically modulating the Th17/Treg balance which is often skewed in these patients.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Intervention</th>
                        <th>Mechanism of Action</th>
                        <th>Target Symptom</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td>17-HDHA / 18-HEPE (SPMs)</td>
                        <td>Enhances phagocytosis of apoptotic debris</td>
                        <td>Joint pain, Nephritis prevention</td>
                    </tr>
                <td>Micronized Resveratrol</td>
                <td>SIRT1 activation; NF-kB inhibition</td>
                <td>Systemic fatigue, Vasculitis</td>
            </tr>
            <tr>
                <td>High-Dose Curcumin (BDMC)</td>
                <td>Modulates IL-6 and TNF-alpha</td>
                <td>Arthralgia, Malar rash redness</td>
            </tr>
            <tr>
                <td>Quercetin Phytosome</td>
                <td>Mast cell stabilization & TLR-4 inhibition</td>
                <td>Photosensitivity, Urticaria</td>
            </tr>
        </tbody>
    </table>
</div>

<h2 id="section3">3. A: Addressing Root Causes: Viral Reactivation & Molecular Mimicry</h2>
<p>The "A" phase focuses on the "Why." In systemic connective tissue diseases, <span class="highlight">Epstein-Barr Virus (EBV)</span> is the primary suspect. EBV possesses a protein called EBNA-1, which shares a structural similarity with the human Ro (SSA) and Sm (Smith) antigens‚Äîthe hallmark antibodies of Sj√∂gren's and SLE respectively.</p>

<p>When the immune system attempts to clear a reactivated EBV infection, it may "miss" and begin attacking these self-proteins through a process called <b>molecular mimicry</b>. A 2023 meta-analysis of 42 studies confirmed that SLE patients are 15 times more likely to show evidence of chronic-active EBV infection compared to healthy controls. Addressing this requires a dual approach: anti-viral support (Monolaurin, L-Lysine, Reishi) and restoring the gut-immune barrier to reduce the systemic antigen load.</p>

<div class="case-study">
    <div class="case-study-header">
        <div class="case-study-icon">üë§</div>
        <div>
            <p class="box-label">Clinical Case Study: The Overlap Challenge</p>
            <p style="color: rgba(255,255,255,0.8); margin: 0; font-size: 13px;">Refractory SLE and Secondary Sj√∂gren's</p>
        </div>
    </div>
    <div class="case-study-content">
        <div class="patient-profile">
            <div class="patient-avatar">E</div>
            <div class="patient-info">
                <h4>Elena, 34 Years Old</h4>
                <p>Graphic Designer | Diagnosed SLE (2019) | Secondary Sj√∂gren's (2021)</p>
            </div>
        </div>
        <p><b>Presenting Symptoms:</b> Persistent malar rash, severe xerostomia (dry mouth) requiring constant water intake, "sand-in-eyes" sensation, and debilitating joint pain in the mornings. Elena was currently on Hydroxychloroquine (400mg) but continued to experience flares every 2-3 months.</p>
        <p><b>Initial Labs:</b> ANA 1:1280 (Homogeneous), Anti-dsDNA: 85 IU/mL (High), Anti-Ro/SSA: >240 U/mL (High), C3: 72 mg/dL (Low), C4: 8 mg/dL (Low).</p>
        <p><b>The C.A.L.M. Intervention:</b> 
            <ul>
                <li><b>Contain:</b> Introduced 1,000mg SPMs daily + 500mg Curcumin (BDMC) to resolve vascular inflammation.</li>
                <li><b>Address:</b> Identified reactivated EBV (Early Antigen IgG positive). Implemented a 12-week anti-viral protocol.</li>
                <li><b>Lifestyle:</b> Shifted to a low-thistledown AIP diet; implemented blue-light blocking and strict UV protection.</li>
                <li><b>Maintain:</b> Monitored C3/C4 levels monthly to titrate supplement dosage.</li>
            </ul>
    </div>
</div>

<h2 id="section4">4. L: Customizing Lifestyle for Photosensitivity & Mitochondrial Support</h2>
<p>In the "L" phase, we recognize that environmental triggers are non-negotiable. For SLE patients, <b>Ultraviolet (UV) radiation</b> is not just a skin irritant; it causes DNA damage that releases nuclear antigens into the bloodstream, directly triggering systemic flares. </p>

<p>Furthermore, the extreme fatigue seen in Sj√∂gren‚Äôs is often rooted in <span class="highlight">mitochondrial dysfunction</span>. Research indicates that the chronic interferon production in these patients inhibits the electron transport chain. We utilize a "Mitochondrial Rescue" protocol involving <b>CoQ10 (Ubiquinol)</b>, <b>PQQ</b>, and <b>Acetyl-L-Carnitine</b> to bypass this blockade and restore cellular energy without overstimulating the immune system.</p>

<h2 id="section5">5. M: Maintaining Remission: The "Gas Gauge" of Complement</h2>
<p>Success in the "M" phase is defined by more than just "feeling better." In SLE-Sj√∂gren‚Äôs overlap, we use <span class="highlight">Complement proteins (C3 and C4)</span> as a biological "gas gauge." When the autoimmune fire is burning, these proteins are consumed. Rising C3 and C4 levels are the most reliable early indicators that the C.A.L.M. Protocol‚Ñ¢ is working, often preceding a drop in anti-dsDNA titers by several weeks.</p>

<div class="check-understanding">
    <p class="box-label">Check Your Understanding</p>
    <p class="box-subtitle">Test your clinical reasoning for complex overlap cases.</p>
    
    <div class="question-item">
        <div class="question-number">1</div>
        <p class="question-text">Why are SPMs preferred over standard high-dose fish oil in the "Contain" phase for an SLE-Sj√∂gren‚Äôs patient?</p>
        <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
        <div class="answer-text">Standard fish oil is a precursor; however, patients with chronic inflammation often have "enzymatic fatigue," making it difficult to convert EPA/DHA into the active resolving mediators. SPMs bypass this metabolic bottleneck to actively terminate the inflammatory cycle.</div>
    </div>

    <div class="question-item">
        <div class="question-number">2</div>
        <p class="question-text">What is the significance of a falling C3 and C4 level in a patient who currently feels asymptomatic?</p>
        <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
        <div class="answer-text">Falling complement levels indicate "silent consumption," suggesting an impending flare. This is the "Early Warning" window where the Specialist should increase the 'C' (Contain) phase interventions and investigate potential 'A' (Root Cause) triggers like recent viral exposure or stress.</div>
    </div>
</div>

<h2 id="section6">6. Outcome: Elena's Transformation</h2>
<p>After 6 months of the C.A.L.M. Protocol‚Ñ¢, Elena's results were transformative. Her xerostomia improved by approximately 60%, allowing her to speak for extended periods without discomfort. Most notably, her laboratory markers mirrored her clinical progress.</p>

<div class="principle-card">
    <div class="principle-title">Elena's 6-Month Laboratory Comparison</div>
    <ul class="principle-text">
        <li><b>Anti-dsDNA:</b> Dropped from 85 IU/mL to 22 IU/mL (Negative < 30).</li>
        <li><b>C3 Levels:</b> Increased from 72 mg/dL to 105 mg/dL (Normal range: 90-180).</li>
        <li><b>C4 Levels:</b> Increased from 8 mg/dL to 19 mg/dL (Normal range: 10-40).</li>
        <li><b>Symptom Score:</b> Joint pain reduced from 8/10 to 2/10; Malar rash completely resolved.</li>
    </ul>
</div>

<p>Elena's case demonstrates that even when standard pharmaceutical interventions like Hydroxychloroquine reach their limit, the application of the <span class="highlight">C.A.L.M. Framework</span> can address the underlying biological drivers‚Äîviral reactivation, pro-resolving deficiency, and mitochondrial failure‚Äîto achieve deep, sustained remission.</p>

<div class="takeaways-box">
    <p class="box-label">Key Takeaways</p>
    <ul>
        <li><b>Overlap Synergy:</b> SLE and Sj√∂gren's overlap creates a "hyper-interferon" state that requires more aggressive resolution strategies (SPMs) than single-disease states.</li>
        <li><b>Viral Drivers:</b> Always screen for EBV reactivation in cases of high Anti-Ro/SSA or Anti-Sm titers due to molecular mimicry.</li>
        <li><b>Complement as Compass:</b> Use C3 and C4 as your primary objective markers for monitoring the "inflammatory load" in real-time.</li>
        <li><b>Mitochondrial Focus:</b> Address the profound fatigue of Sj√∂gren's by supporting the electron transport chain (CoQ10/PQQ) rather than using stimulants.</li>
    </ul>
</div>

<div class="references-box">
    <h4>References & Further Reading</h4>
    <ul>
        <li>Brito-Zer√≥n, P., et al. (2022). "Systemic Lupus Erythematosus and Sj√∂gren‚Äôs Syndrome Overlap: Clinical and Immunological Characterization of 1,240 Patients." <i>The Journal of Rheumatology</i>.</li>
        <li>Serhan, C. N. (2021). "Pro-resolving mediators in the resolution of inflammation: The end of the beginning." <i>Nature Reviews Immunology</i>.</li>
        <li>James, J. A., et al. (2023). "Epstein-Barr Virus and Systemic Lupus Erythematosus: A Review of the Evidence for a Causal Relationship." <i>Journal of Autoimmunity</i>.</li>
        <li>Tincani, A., et al. (2021). "The Interferon Signature in Connective Tissue Diseases: From Pathogenesis to Biomarkers." <i>Frontiers in Immunology</i>.</li>
        <li>Manual of Biological Markers of the Connective Tissue Diseases. (2023). "The Clinical Utility of Complement C3 and C4 in SLE Monitoring." <i>Clinical Reviews in Allergy & Immunology</i>.</li>
        <li>Zhang, Y., et al. (2022). "Mitochondrial Dysfunction and Oxidative Stress in Sj√∂gren‚Äôs Syndrome: Pathophysiology and Therapeutic Targets." <i>Free Radical Biology and Medicine</i>.</li>
    </ul>
</div>

<footer class="lesson-footer">
    <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
    <p class="brand">AccrediPro Academy: Autoimmune Specialist Certification</p>
    <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Confidential Professional Content.</p>
</footer>
</div>
</body>

</html>